TABLE 2.

Central versus local MICs of qualifying baseline pathogens for patients included in the SmMITT population but excluded from the mMITT population^b

Patient no.	TG	Infection type	Qualifying pathogen name	Local interpretive criteria used	MIC (μg/ml [susceptibility])c
					Imipenem		IMI-REL		Colistin
					Local lab	Central lab	Local lab	Central lab	Local lab	Central lab
1	2	HABP/VABP	E. aerogenes	CLSI	2 (I)	1 (S)	0.5 (S)	0.12 (S)	0.25 (S)	<1 (S)
2a	1	cIAI	K. pneumoniae	EUCAST	8 (I)	4 (I)	2 (S)	2 (S)	2 (S)	4 (R)
3	2	cIAI	E. cloacae	CLSI	2 (I)	<0.5 (S)	0.5 (S)	0.12 (S)	1 (S)	<1 (S)
4	1	cIAI	E. cloacae	CLSI	2 (I)	<0.5 (S)	1 (S)	0.12 (S)	1 (S)	<1 (S)
5	1	cIAI	K. pneumoniae	CLSI	4 (R)	4 (R)	1 (S)	2 (I)	0.5 (S)	<1 (S)
6	1	cUTI	E. coli	CLSI	2 (I)	2 (I)	1 (S)	2 (I)	0.12 (S)	<1 (S)
7	2	cUTI	K. pneumoniae	CLSI	2 (I)	2 (I)	1 (S)	2 (I)	0.12 (S)	<1 (S)
8	1	cUTI	K. pneumoniae	CLSI	16 (R)	32 (R)	1 (S)	2 (I)	0.25 (S)	<1 (S)
9	1	cUTI	P. aeruginosa	CLSI	8 (R)	2 (S)	2 (S)	0.5 (S)	1 (S)	<1 (S)
10	1	cUTI	P. aeruginosa	CLSI	16 (R)	2 (S)	1 (S)	0.25 (S)	0.12 (S)	<1 (S)

^aThe participant had a polymicrobial infection, including an infection caused by a qualifying P. aeruginosa isolate, but was unevaluable for the mMITT population due to the presence of colistin-nonsusceptible K. pneumoniae.

^bcIAI, complicated intra-abdominal infection; CLSI, Clinical and Laboratory Standards Institute; cUTI, complicated urinary tract infection; EUCAST, European Committee on Antimicrobial Susceptibility Testing; HABP, hospital-acquired bacterial pneumonia; I, intermediate; IMI-REL, imipenem-cilastatin plus relebactam; mMITT, microbiological modified intent-to-treat; R, resistant; S, susceptible; SmMITT, supplemental microbiological modified intent-to-treat; TG, treatment group; VABP, ventilator-associated bacterial pneumonia.

^cData in boldface indicate differences in susceptibility test interpretation (susceptible versus intermediate versus resistant) between the local laboratory and central laboratory, based on MIC values.